AMIX Stock Forecast: Autonomix Medical, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Autonomix Medical, Inc. is $41. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 31 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Autonomix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (86): Analysts have, on balance, been raising their forecasts.
Volatility (3): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AMIX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AMIX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Feb 2026 | Maxim Group | Maintains | Buy | $5.00 → $2.00 |
| 29 Apr 2025 | Maxim Group | Initiates | Buy | — |
| 3 Sept 2024 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AMIX.
This page is one stock. Monday covers all of them.
AMIX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AMIX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 93% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −176.0%
- Return on assets
- −93.2%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Autonomix Medical, Inc. has a market value of $1.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$16.1M.
Free cash flow in the twelve months to 30 June 2026: −$13.2M.
Autonomix Medical, Inc. employs 8 people.
Data provided by Twelve Data
AMIX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AMIX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Autonomix Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AMIX
What is the AMIX stock price forecast for 2026-2027?
The median 12-month analyst price target for Autonomix Medical, Inc. is $41, with estimates ranging from $6 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AMIX stock a buy right now?
Of the 2 analysts covering Autonomix Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Autonomix Medical, Inc. 31 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AMIX?
As at 21 Nov 2026, Autonomix Medical, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).
Will AMIX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $41, and Ticker Nerd's factor model ranks Autonomix Medical, Inc. 31 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AMIX stock forecast for 2030?
No analyst covering Autonomix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $76 over the next 12 months.
What does Autonomix Medical, Inc. do?
Autonomix Medical Inc. is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its current platform centers on a catheter-based, microchip-enabled sensing array designed to detect and differentiate neural signals with high sensitivity from within the vascular system.
About Autonomix Medical, Inc.
Autonomix Medical Inc. is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its current platform centers on a catheter-based, microchip-enabled sensing array designed to detect and differentiate neural signals with high sensitivity from within the vascular system. The company is developing this technology for applications in pancreatic cancer and pancreatitis, while also addressing areas such as chronic pain management, hypertension, cardiovascular conditions, and other nerve-related disorders. Autonomix Medical Inc. operates as a single-segment business dedicated to improving how neural conditions are diagnosed and treated through minimally invasive, signal-detection-based tools. Headquartered in The Woodlands, Texas, Autonomix Medical Inc. serves the medical technology market with a specialized focus on nerve-targeted interventions and disease management.
CEO Mr. Bradley Hauser · 8 employees · United States · https://autonomix.com